Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: indication (643), sign (706), indicator (112)

Vitamin K supplements for newborn babies - patient information

Description: This factsheet explains what vitamin K is, why it is recommended for newborn babies and what your options are when your
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Vitamin-K-supplements-for-newborn-babies-2143-PIL.pdf

Your baby's movements - patient information

Description: This factsheet contains information about your baby's movements during pregnancy.
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Your-babys-movements-3102-PIL.pdf

Epcoritamab -Cycle 1 (Priming)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB -Cycle 1 - (28 Day -Priming) Regimen • Lymphoma-Epcoritamab – Cycle 1- (28 day -Priming) Indicati
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-1-Priming-Ver1.pdf

VR-RituximabVenetoclaxCycle_1_VenetoclaxDoseTitration

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) Cycle 1 – Venetoclax dose titration Regimen • CLL – VR R
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclaxCycle-1-VenetoclaxDoseTitration.pdf

ACCORD-2 master protocol

Description: CONFIDENTIAL ACCORD-2-001 – Master Protocol TITLE PAGE Protocol Title: ACCORD-2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to
Url: /Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-master-protocol.pdf

Elranatamab

Description: Chemotherapy Protocol ELRANATAMAB This protocol may require funding Regimen • Elranatamab Indication • Monotherapy for t
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Elranatamab-Ver2.pdf

Epcoritamab -Cycle 2 (Onwards)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB – Cycle 2 Onwards - (28 day) Regimen • Lymphoma-Epcoritamab – Cycle 2 Onward
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-2-Onwards-Ver1.pdf

Low pregnancy associated plasma protein-A (PAPP-A) - maternity information

Description: This factsheet explains what pregnancy associated plasma protein-A (PAPP-A) is and what a low level of PAPP-A means
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Low-pregnancy-associated-plasma-protein-A-PAPP-A-3691-PIL.pdf

Isatuximab VRD weekly

Description: Chemotherapy Protocol Myeloma Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-Dexamethasone (20) Regimen Myeloma – Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-D
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Isatuximab-VRD-weekly-Ver1.pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description: Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone I
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf

1 to 10 of 133

Previous 1 2 3 4 5 … Next